Loading…
CIK 0002010850 • 6 13F filings • May 8, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("decheng-capital-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| 4D MOLECULAR THERAPEUTICS IN | COM | $332K | 0.0%Prev: 0.1% | 44,311 SH | Decreased-48,437 SH |
| AARDVARK THERAPEUTICS INC | COM | $51.4M | 6.9%Prev: 9.1% | 3,917,299 SH | Decreased |
| Aclaris Therapeutics, Inc. | COM | $12.2M | 1.6%Prev: 1.3% | 4,041,736 SH | Increased |
| Arcus Biosciences, Inc | COM | $12.9M | 1.7%Prev: 1.3% | 541,559 SH | Increased-6,050 SH |
| Aura Biosciences, Inc. | COM | $2.0M | 0.3%Prev: 0.6% | 360,483 SH | Decreased-155,072 SH |
| BeyondSpring Inc. | SHS | $6.2M | 0.8%Prev: 1.4% | 3,800,702 SH | Decreased-485,402 SH |
| CG ONCOLOGY INC | COM | $264.6M | 35.6%Prev: 44.8% | 6,371,669 SH | Increased |
| CRINETICS PHARMACEUTICALS IN | COM | $4.3M | 0.6%Prev: 1.0% | 92,700 SH | Decreased-50,300 SH |
| Equillium Inc. | COM | $6.9M | 0.9%Prev: 1.1% | 4,447,308 SH | Increased |
| KRYSTAL BIOTECH INC | COM | $4.3M | 0.6%Prev: 1.0% | 17,300 SH | Decreased-15,000 SH |
| Lyell Immunopharma, Inc. | COM | $21.3M | 2.9%Prev: 1.7% | 692,050 SH | Increased+96,584 SH |
| NEWAMSTERDAM PHARMA CO NV | COM | $20.8M | 2.8%Prev: 3.3% | 592,057 SH | Increased-64,994 SH |
| Nuvation Bio Inc. | COM | $232.6M | 31.3%Prev: 16.8% | 25,954,439 SH | Increased |
| Nuvation Bio Inc. | WARRANTS | $213K | 0.0%Prev: 0.0% | 646,057 SH | Increased |
| Pyxis Oncology, Inc (formerly Apexigen) | COM | $376K | 0.1%Prev: 0.1% | 326,810 SH | Decreased |
| REVOLUTION MEDICINES INC(NSM) | COM | $15.9M | 2.1%Prev: 1.7% | 200,000 SH | Increased-10,000 SH |
| REZOLUTE INC | COM | $141K | 0.0%Prev: 0.1% | 59,900 SH | Decreased |
| Upstream Bio Inc. | COM | $85.3M | 11.5%Prev: 10.8% | 3,143,078 SH | Increased-142,215 SH |
| Zentalis Pharmaceuticals Inc. | COM | $1.8M | 0.2%Prev: 0.3% | 1,323,327 SH | Decreased |
| 13F-HR |
| 0001104659-26-096837 |
| $731.7M |
| View |
| Aug 13, 2025 | Q2 2025 | 13F-HR | 0001104659-25-077492 | $396.0M | View |
| May 13, 2026 | Q1 2026 | 13F-HR | 0001104659-26-060145 | $661.3M | View |
| May 8, 2025 | Q1 2025 | 13F-HR | 0001104659-25-045686 | $356.5M | View |